Loey Yi 麥龍兒

  • Fellowship in 2021 at Barts Liver Centre, Blizard Institute

Dr Mak is a Clinical Assistant Professor in the Department of Medicine, The University of Hong Kong. She is a specialist in Gastroenterology and Hepatology and provides clinical service in Queen Mary Hospital, Hong Kong. Dr Mak graduated from high school scoring all 5 subjects with grade A in the HKALE in year 2006. She received her primary medical education at The University of Hong Kong. She obtained her qualification of the Membership of the Royal Colleges of Physicians of the United Kingdom in 2013 and the Postgraduate Diploma in Infectious Diseases by The Li Ka Shing Faculty of Medicine of The University of Hong Kong in 2015. She completed her specialty training in Gastroenterology and Hepatology in year 2018 and Advanced Internal Medicine in year 2019 at Queen Mary Hospital. She obtained the degree of Doctor of Medicine in year 2021 in HKU.

Dr Mak’s research interests include chronic hepatitis B, fibrosis assessment and treatment of chronic liver diseases, and biomarkers in gastrointestinal diseases. She has published more than 50 first-authored peer-reviewed articles in reputable journals. Highlights include 3 first-authored/ co-first-authored original articles and a review article in Journal of Hepatology (impact factor 30.083), and Hepatology (impact factor 17.298), respectively. She currently served as the editorial board member for Hepatology Communications and Frontiers in Immunology.

Dr Mak has received numerous academic awards, including the Dr Kate Cheng Memorial Prize for Postgraduate Diploma in Infectious Diseases, the Best Abstract in Clinical Medicine in the Medical Research Conference organized by The University of Hong Kong in 2017, 2019 and 2020, and 2021, the Young Investigators Award in the Asian Pacific Association of Gastroenterology 3rd Clinical Forum on Inflammatory Bowel Disease in 2018, and the travel award for the 7th Annual Meeting of Asian Organization of Crohn's & Colitis. She was also awarded the Faculty Knowledge Exchange Award by Li Ka Shing Faculty of Medicine, The University of Hong Kong in 2019. She won the Young Investigator’s Award in the 30th Conference of the Asian Pacific Association for the Study of the Liver, and the Distinguished Research Paper Award by the Hong Kong College of Physicians in year 2020. Her research paper was awarded with the Faculty Outstanding Research Output Award by The LKS Faculty of Medicine in year 2021 and the Lo Ying Shek Chi Wai Foundation Award for Young Investigator 2020-2021. She was awarded with the Young Investigator Bursary by the European Association for Study of the Liver in year 2021 and 2022. Internationally, she was awarded with the Best Oral Presentation Award in the 32nd Conference of The APASL 2023 annual meeting. She is also selected to receive the prestigious EASL Emerging Leader Award in 2023.

Dr Mak is currently the honorary treasurer of The Hong Kong Association for Study of Liver Disease. She is also an Associate Member, of the State Key Laboratory of Liver Research, The University of Hong Kong.

Representative publications

1. Lee CH*, Mak LY*, Tang EHM*, Lui DTW, Mak JHC, Li L, Wu T, Chan WL, Yuen MF, Lam KSL, Wong CKH. SGLT2i reduces risk of developing HCC in patients with co-existing T2D and CHB infection – A territory-wide cohort study in Hong Kong. Hepatology 2023; in press (*Co-first authors)

2. Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri B, Cusi K, Loomba R, Given B, Christianson D, Garcia-Medel E, Yi M, Martin JS, Hamilton J, Yuen MF. ARO-HSD, an RNA interference therapeutic for the treatment of non-alcoholic steatohepatitis: a phase 1/ 2 study. J Hepatol 2023; 78: 684-692.

3. Mak LY, Hui RWH, Lee CH, Mao X, Cheung KS, Wong DKH, Lui DTW, Fung J, Yuen MF, Seto WK. Glycemic burden and the risk of adverse hepatic outcomes in chronic hepatitis B patients with type 2 diabetes. Hepatology 2022; in press

4. Wong CKH*, Mak LY*, Au ICH, Lai FTT, Li X, Wan EYF, Chui CSL, Chan EWY, Cheng WY, Cheng FWT, Yuen MF, Wong ICK. No increase in risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines: A self-controlled case series study. J Hepatology 2022; 77:1339-1348 (*Co-first authors)

5. Mak LY, Cheung KS, Hui RWH, Wong DKH, Fung J, Seto WK, Yuen MF. Enhanced liver fibrosis score stratifies hepatocellular carcinoma risk in patients with hepatitis B surface antigen seroclearance. Clin Infect Dis 2022; 75: 2257-2259.

6. Mak LY, Cloherty G, Wong DKH, Gersch J, Seto WK, Fung J, Yuen MF. HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology 2021; 73:2169-2179.

7. Mak LY, Yuen MF, Seto WK. Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”. J Hepatol 2020; 73:1573-1574.

8. Mak LY, Wong DKH, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol 2020; 73:952-64.

9. Mak LY, Hui RWH, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 2020; 73:800-806.

10. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther 2017; 47:43-54.